报告人：朱光宇教授

主持人：王志刚

时间：2022年8月9号 16:30-17：30

地点：腾讯会议（ID号：647-882-497）

报告人简介：         

Dr. Guangyu Zhu is an Associate Professor at the Department of Chemistry, City University of Hong Kong. Dr. Zhu’s research interest lies at the interface of chemistry and biology, focusing on anticancer drug development and mechanism. His current research projects include development of photoactivatable anticancer prodrugs, synthesis and biological evaluation of novel metal-based anticancer agents, and development of cancer-specific nanomedicine to conquer cisplatin resistance. His research work has been published in Nature series, Chem, JACS, Angew, PNAS, etc. Currently he is the Editorial Advisory Board member of the Journal of Biological Inorganic Chemistry and member of Asian Biological Inorganic Chemistry (AsBIC) Steering Committee.

报告内容：Despite the broad clinical applications of platinum-based anticancer drugs including cisplatin, their side effects and resistance issues have encouraged researchers to look for novel metal-based anticancer complexes. Non-traditional platinum compounds, especially Pt(IV) complexes, have been extensively studied, and they hold great promise to be further developed as the next-generation platinum drugs. Controllable activation of prodrugs within a tumor is particularly attractive because of their low damage to normal tissue. In this presentation, I will introduce the design, photoactivation mechanism, and antitumor activity of visible light-activatable Pt(IV) prodrugs. These small-molecule prodrugs have controllable activation properties and display superior antitumor activity both in vitro and in vivo. In addition, our recent progress in erythrocyte-delivered Pt(IV) prodrug and nanoprodrug for enhanced circulation will also be introduced. The controllable activation property and superior antitumor activity of these prodrugs may suggest a practical way to reduce the adverse effects and conquer drug resistance of traditional platinum chemotherapy.